Also, whats the potential impact on Narayana as they mostly do specilised treatments/surgeries? Current fall in NH share on the back of this development offers good margin of safety, given the company is consistently growing at 20% EPS and valuation (EV/EBITDA) appears reasonable vs peers.
Any thoughts?
Subscribe To Our Free Newsletter |